Media

September 6 2023

Verismo Therapeutics Doses First Patient in Groundbreaking SynKIR-110 Clinical Trial for Advanced Cancers

MORE >

August 22 2023

Verismo Therapeutics and University of Pennsylvania Discover Two Novel Binders Targeting CD19; Enter Licensing Agreement

MORE >

June 13 2023

Verismo Therapeutics and the Center for Vaccine and Cell Production Facility (CVPF) at the University of Pennsylvania Forge Manufacturing Relationship

MORE >

May 17 2023

Verismo Therapeutics Welcomes Sara Weiss as Senior Vice President of Clinical Operations

MORE >

May 2 2023

Verismo Therapeutics Announces the Activation of its STAR-101 Clinical Trial at the University of Pennsylvania

MORE >

April 13 2023

Verismo Therapeutics Presents STAR-101 Clinical Trial Design at the Annual Cholangiocarcinoma Foundation Conference

MORE >

April 5 2023

Verismo Therapeutics Secures Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110

MORE >

February 28 2023

Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor

MORE >

January 3 2023

Verismo Therapeutics Expands Quality and Compliance Team

MORE >

January 3 2023

Verismo Therapeutics Expands Quality and Compliance Team

MORE >